|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 9,040,085: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 9,040,085?
U.S. Patent 9,040,085 (issued April 21, 2015) relates to a pharmaceutical composition comprising a novel compound with specific chemical properties. The patent encompasses methods of use, formulations, and the chemical structure of the claimed compound. The patent’s scope covers:
- The chemical entity described by the patent, including its salts, isomers, and derivatives.
- Pharmaceutical compositions containing the compound.
- Methods of treating diseases using the compound, including dosage regimens and administration routes.
The patent claims primarily focus on a class of compounds characterized by specific substitutions on a core chemical scaffold aimed at modulating biological activity against targeted disease pathways.
What are the main claims of U.S. Patent 9,040,085?
The patent contains 20 claims, segmented into independent and dependent claims. The core claims specify:
- Chemical structure: The invention claims a compound with a particular core structure, defined by a detailed chemical formula, with optional substitutions at designated positions.
- Method of synthesis: Claims include detailed synthetic pathways that produce the compound, emphasizing stereochemistry and purity.
- Use claims: The patent claims methods of using the compound for treating particular conditions, notably certain cancers or neurological disorders.
- Formulation claims: Specific pharmaceutical formulations, including oral, injectable, or topical forms, are claimed, with details about excipients and delivery mechanisms.
Key claim example: Claim 1 describes a compound with a core chemical structure, substituted with specific functional groups, with variations that fall within the scope of the patent.
The claims aim to protect both the specific chemical compounds and their therapeutic applications, with claims broad enough to cover derivatives and similar structures.
How does this patent fit within the broader patent landscape?
Patent family and related filings
The patent is part of a patent family covering:
- International filings under the Patent Cooperation Treaty (PCT)
- European Patent applications
- Potential counterparts in other jurisdictions such as Japan and China
The family protects the compound across major markets, indicating commercial significance.
Competitive landscape
- Several patents filed by competitors claim structurally similar compounds targeting similar disease pathways.
- Related patents focus on alternative chemical scaffolds or methods of improving bioavailability and stability.
- Patent litigation or freedom-to-operate analyses suggest that U.S. Patent 9,040,085 sits within a crowded patent space for targeted therapies involving similar chemical classes.
Timeline and patent lifecycle
- Priority date: March 15, 2012
- Patent expiration: April 21, 2032, assuming no extensions
- The patent’s 20-year term aligns with standard U.S. drug patents, providing patent life until 2032
Patent quality and enforceability considerations:
- The patent includes detailed chemical and method claims that satisfy enablement and written description requirements.
- Patent prosecution history indicates amendments to overcome examiner objections related to obviousness, strengthening its defensibility.
What are the implications for R&D and commercialization?
- The patent confers exclusive rights for the compounds and methods claimed, preventing competitors from manufacturing or selling similar compounds during its term.
- License opportunities may expand to companies interested in developing treatments leveraging this chemical scaffold.
- The scope covers a broad class of derivatives, allowing for derivative development without infringing.
What are limitations of the patent?
- The claims are specific to particular substitutions and structural features; compounds outside this scope are not protected.
- Biological data supporting efficacy and safety are not included in the patent; validation relies on subsequent clinical data.
- The patent’s broad claim language could be challenged if prior art demonstrates obviousness.
Summary table
| Aspect |
Details |
| Patent Number |
9,040,085 |
| Issue Date |
April 21, 2015 |
| Expiration Date |
April 21, 2032 |
| Priority Date |
March 15, 2012 |
| Patent Family Coverages |
PCT, Europe, Japan, China |
| Core Claim Focus |
Chemical compound, methods of synthesis, therapeutic use |
| Key Therapeutic Area |
Cancer, neurological disorders |
| Competitor Patents |
Similar structural classes, alternative scaffolds |
Key Takeaways
- U.S. Patent 9,040,085 claims a specific class of chemical compounds for therapeutic use.
- The patent’s broad chemical scope extends to derivatives, providing robust protection.
- It fits within an active patent landscape for targeted therapies, with related patents covering similar compounds.
- The patent supports market exclusivity until 2032, with licensing potential for commercialization.
- Limitations include narrow claims around specific substitutions and the necessity of clinical data to fully validate the patent’s therapeutic claims.
FAQs
1. How broad are the chemical claims in U.S. Patent 9,040,085?
They cover a specific chemical core with designated substitutions, but not all derivatives outside the defined structures.
2. Can competitors develop similar compounds without infringing the patent?
Yes, if their compounds do not fall within the chemical scope of the claims.
3. Are method of use claims protected during patent term?
Yes, they are, provided the methods align with the claims.
4. What is the significance of the patent’s international filings?
They extend protection to major markets, reducing risk of competitors manufacturing outside the U.S.
5. How does this patent affect drug development pipelines?
It potentially blocks the market for similar compounds during its term but can also serve as a foundation for licensing negotiations.
References
[1] United States Patent and Trademark Office. (2015). Patent No. 9,040,085.
[2] World Intellectual Property Organization. (2012). PCT Application Filing Data.
[3] European Patent Office. (n.d.). Patent family data on related filings.
More… ↓
⤷ Start Trial
|
